Indapamide

Introduction Overview

Generic Name

indapamide

Brand Name

Lozol

Dosage Form

oral tablet (1.25 mg; 2.5 mg)

Drug Class

thiazide diuretics

Pharmacokinetics

Absorption:
Indapamide is well absorbed following oral administration with bioavailability generally reported to be high, allowing efficient systemic exposure. It reaches peak plasma levels within 1.5 to 2 hours post-dose. The rate of absorption is not significantly affected by food intake, enabling flexible dosing relative to meals. However, variability between patients can occur due to individual gastrointestinal conditions. The drug’s onset of diuretic effect usually occurs within 2 hours, peaking around 4 to 6 hours and lasting approximately 24 hours, which supports once-daily dosing.

Distribution:
Once absorbed, indapamide exhibits extensive distribution into body tissues, particularly renal tissue where it exerts its pharmacologic effects. Plasma protein binding ranges from 71% to 79%, mainly to albumin, which influences its transport and duration of action. The volume of distribution is moderate, reflecting both plasma and peripheral tissue binding. Indapamide’s affinity for renal tissue supports its efficacy as a diuretic targeting the kidney’s distal tubules.

Metabolism:
Indapamide undergoes hepatic metabolism primarily via cytochrome P450 enzymes, producing inactive metabolites. The metabolic pathways include oxidation and conjugation, with limited formation of pharmacologically active metabolites. Liver function can influence the rate of metabolism; thus, patients with hepatic impairment may experience altered pharmacodynamics and require dose adjustment. However, the parent compound is mainly responsible for the therapeutic effect.

Elimination:
Indapamide and its metabolites are excreted via renal and biliary routes. Approximately 20-30% of the dose is excreted unchanged in the urine, while the remainder is eliminated as metabolites via urine and feces. The elimination half-life ranges from 14 to 25 hours, supporting once-daily administration. Renal impairment can prolong elimination, necessitating careful monitoring. Indapamide’s clearance is influenced by kidney function but is generally effective and safe in mild to moderate impairment when dosed appropriately.

Dosage Forms

Available Dosage Forms:
Indapamide is marketed as oral tablets with strengths of 1.25 mg and 2.5 mg. These tablets are designed for oral administration, enabling convenient once-daily dosing.

Dosages for Adults and Adolescents:
For the treatment of edema, the usual adult initial dose is 2.5 mg once daily orally. In hypertension management, the initial dose typically starts at 1.25 mg once daily, which may be titrated based on clinical response and tolerability. Dose adjustments should be made cautiously, considering the narrow therapeutic index and potential for electrolyte disturbances.

Specific Patient Populations:
Dosing in elderly patients generally follows adult dosing guidelines but requires close monitoring due to potential altered pharmacokinetics and increased susceptibility to adverse effects, particularly electrolyte imbalances and dehydration. Indapamide is not approved for use in pediatric populations under 18 years of age. In patients with renal or hepatic impairment, dose adjustments and monitoring of kidney and liver function are essential to avoid toxicity. Pregnant women should use indapamide only if the potential benefit justifies the potential risk to the fetus; it is not known if the drug passes into breast milk, and therefore breastfeeding is generally not recommended during therapy.

Mechanism Of Action

Indapamide is a thiazide-like diuretic that exerts its primary therapeutic effect by inhibiting sodium and chloride ion reabsorption in the distal convoluted tubules of the nephron. This inhibition reduces sodium retention, thereby promoting natriuresis and consequent diuresis. The loss of sodium and water leads to a reduction in extracellular fluid volume, which contributes to decreased blood pressure and edema reduction.

At the molecular level, indapamide targets the sodium-chloride symporter (NCC) at the luminal membrane of distal convoluted tubular cells. By blocking this transporter, indapamide impedes the reuptake of sodium and chloride ions, causing increased excretion of these ions along with water. This action reduces plasma volume and diminishes preload and afterload on the heart.

Beyond its diuretic effects, indapamide has been shown to have vasodilatory properties. It promotes the relaxation of vascular smooth muscle through mechanisms that may involve calcium channel modulation and reduction of peripheral vascular resistance. This vasodilatory action contributes significantly to its antihypertensive effects, making it more efficacious in lowering blood pressure compared to some other diuretics.

Clinically, the combination of diuresis and vasodilation provides a dual benefit in conditions like hypertension and congestive heart failure. Research studies suggest that indapamide’s unique pharmacological profile results in a favorable side effect profile and better metabolic neutrality compared with traditional thiazide diuretics. Comparative clinical trials have demonstrated its efficacy in preventing cardiovascular events, supporting its role as a first-line agent in hypertension management.

Pharmacological Actions

Inhibits sodium and chloride reabsorption in distal convoluted tubules leading to increased diuresis.
Promotes natriuresis resulting in reduction of extracellular fluid volume and edema.
Exerts vasodilatory effects by relaxing vascular smooth muscle, contributing to decreased peripheral vascular resistance.
Reduces blood pressure through combined diuretic and vascular smooth muscle effects.
Modulates electrolyte balance, particularly sodium and potassium homeostasis.
Demonstrates minimal adverse metabolic effects compared to other thiazide diuretics.
Improves cardiac preload and afterload conditions in congestive heart failure.
Enhances renal sodium clearance thereby helping in volume control.
May modulate calcium channels contributing to vascular effects.
Demonstrates secondary effects on peripheral circulation improving vascular compliance.

Therapeutic Or Clinical Uses

Management of essential hypertension to reduce elevated blood pressure.
Treatment of edema associated with congestive heart failure.
Management of edema related to hepatic cirrhosis and renal disorders.
Adjunct therapy in conditions characterized by fluid retention.
Use in patients requiring salt and water elimination to prevent volume overload.
Alternative diuretic for patients intolerant to other thiazide diuretics.
Reduction of cardiovascular morbidity associated with hypertension.
Control of blood pressure to decrease risk of stroke and myocardial infarction.
Therapeutic use in elderly hypertensive patients due to tolerability profile.
Occasional off-label pediatric or specialized uses under strict medical supervision (although generally not approved).

Side Or Adverse Effects

Dizziness, especially upon standing due to orthostatic hypotension.
Weakness and fatigue associated with electrolyte imbalance.
Muscle cramps and back pain due to altered potassium and magnesium levels.
Headache and possible transient anxiety or agitation.
Electrolyte disturbances including hypokalemia, hyponatremia, and occasional hypercalcemia.
Gastrointestinal symptoms such as nausea, vomiting, constipation, or dry mouth.
Increased thirst due to diuretic-induced fluid loss.
Rare allergic reactions including rash and hypersensitivity.
Potential for increased blood glucose and uric acid levels causing hyperglycemia or gout exacerbation.
Possible electrolyte-related cardiac arrhythmias, including palpitations or irregular heartbeats.
Dehydration leading to decreased urine output and light-headedness.
Confusion or cognitive disturbances in susceptible patients due to fluid and electrolyte shifts.
Potential skin photosensitivity reactions under prolonged sun exposure.
Rare but serious allergic reactions such as angioedema and swelling of face or tongue.

Precautions

Use cautiously in patients with pre-existing electrolyte imbalances, especially hypokalemia or hyponatremia.
Monitor kidney and liver function regularly during therapy.
Avoid use in patients unable to urinate, due to risk of fluid and electrolyte disturbances.
Monitor blood pressure closely to avoid symptomatic hypotension or orthostatic hypotension.
Careful monitoring in patients with gout or hyperuricemia, as indapamide may increase uric acid levels.
Cautious use in diabetic patients, as blood glucose tolerance may be altered.
Adjust dosage in elderly patients due to increased sensitivity and altered pharmacokinetics.
Ensure adequate hydration while avoiding dehydration, especially during illness or heat exposure.
Avoid sudden discontinuation to prevent rebound hypertension or fluid retention.
Use with caution in patients on low-sodium diets or other medications affecting electrolyte balance.
Pregnancy monitoring recommended; use only if clearly needed.
Advise patients about signs of electrolyte imbalance and dehydration.
Regularly assess for signs of allergic reactions, especially in sulfa-sensitive individuals.
Breastfeeding is generally not recommended during treatment due to unknown excretion in milk.

Warnings

Contraindicated in patients allergic to sulfonamide-derived drugs due to risk of severe hypersensitivity reactions.
Avoid use if unable to urinate or have severe renal impairment.
Risk of severe electrolyte imbalance leading to cardiac arrhythmias and neurologic symptoms.
Use caution in patients with liver disease or cirrhosis as it may precipitate encephalopathy or electrolyte disturbances.
Potential to cause symptomatic hypotension, particularly in volume-depleted or elderly patients.
May exacerbate gout attacks due to hyperuricemia.
Monitor closely during conditions causing excessive fluid or electrolyte loss such as vomiting, diarrhea, or sweating.
Not for use in pediatric patients under 18 years due to insufficient safety and efficacy data.
Risk of dehydration and hypotension if fluid intake is inadequate during therapy.
Patients should be warned about potential dizziness and advised to avoid sudden position changes.
Concomitant use with other potassium-altering drugs requires careful electrolyte monitoring.
Avoid use during breastfeeding due to unknown risks to the infant.
Potential photosensitivity reactions warrant sun protection measures during exposure.
Use caution with other antihypertensive agents to avoid additive hypotensive effects.

Contraindication

Known hypersensitivity to indapamide or any component of the formulation.
Allergy to sulfonamide or sulfa-derived drugs.
Anuria or inability to urinate.
Severe renal impairment with oliguria or anuria.
Severe hepatic impairment or hepatic coma.
Hypersensitivity to other thiazide or sulfonamide diuretics.
Untreated hypokalemia or hyponatremia prior to initiation of therapy.
Patients with symptomatic hypotension or severe dehydration.
Pregnant women when potential risks outweigh benefits unless under strict medical supervision.
Pediatric patients under 18 years of age (due to lack of established safety).
Concomitant use with potassium-sparing diuretics without monitoring due to risk of hyperkalemia (relative contraindication).
Uncorrected electrolyte imbalances such as severe hyponatremia.
Patients with history of severe allergic reactions to similar diuretics.

Drug Interactions

Digoxin and digitalis glycosides – risk of arrhythmias increases with hypokalemia induced by indapamide.
Lithium – risk of lithium toxicity due to altered renal clearance.
Other antihypertensive agents – additive blood pressure lowering effects leading to hypotension.
Corticosteroids such as prednisone – may potentiate hypokalemia.
NSAIDs – may reduce diuretic and antihypertensive effects of indapamide.
Drugs affecting electrolyte balance (e.g., other diuretics, laxatives) – increased risk of electrolyte disturbances.
Antidiabetic drugs – indapamide may alter glucose tolerance, requiring dose adjustments.
Antiarrhythmics – risk of arrhythmias increases especially in presence of electrolyte imbalance.
Cholestyramine and colestipol – may reduce absorption of indapamide.
Cyclosporine – may augment nephrotoxicity risks.
Non-depolarizing muscle relaxants – may have altered pharmacodynamics.
Quinidine and other drugs that prolong QT interval – risk of torsades de pointes enhanced by electrolyte disturbances.
Alcohol or sedatives – may enhance hypotensive effects and dizziness.
CYP450 enzyme inducers or inhibitors – potential to alter indapamide metabolism.
Sodium-containing drugs or foods – may antagonize diuretic effects.

Preparations Of The Drug

Oral tablets available in strengths of 1.25 mg and 2.5 mg formulated for once-daily dosing.
Tablets designed with appropriate excipients to ensure stability and bioavailability.
Packaged in bottles or blister packs protecting from moisture and light.
Formulations intended for oral administration with standard storage at room temperature.
Commercial preparations marketed under the brand name Lozol.
No injectable or intravenous forms commonly available or recommended.
Extended-release formulations are not standard; immediate-release tablets primarily utilized.
Generic versions available with equivalent bioequivalence to branded formulations.
Preparations often combined with other antihypertensive agents in fixed-dose formulations in certain regions (though not universally available).
Manufactured under strict GMP conditions maintaining quality and potency.